Skip to content

Novo

Danish pharmaceutical company

NOVO Nasdaq Copenhagen · home listing NVO NYSE ISIN DK0060534915 LEI 549300DAQ1CVT6CXN342

Follow Novo Weekly email: filings, results, news

News

7 stories filed under Novo, grouped into ongoing threads

Licensing deal

Thread · 3 stories · active today

Nanexa shares rocket 114% on $1.3 billion Novo Nordisk licensing deal

Markets 15 h ago 2 sources

STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more

Markets 16 h ago

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Markets 20 h ago

More coverage

Viatris sues Novo Nordisk over generic Wegovy patent dispute

Markets 10 h ago also on VTRS

This week in charts: Novo’s rise and fall and AI biotechs’ big haul

Tech 13 h ago

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Markets 16 h ago

Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine

Markets 1 d ago

Profile

Headquarters: Bagsværd, Denmark
Legal name: NOVO NORDISK A/S
Founded: 1923
CEO: Mike Doustdar
Employees: 68,794
Sector: Healthcare
Industry: pharmaceutical industry
LEI: 549300DAQ1CVT6CXN342
Website: novonordisk.com

Peers

Where this page comes from

Profile · GLEIF, Wikidata

News · 7 stories clustered from the RSS aggregator